[Clinical evaluation of the hypotensive effectiveness of Betoptic preparation].
Clinical trials of the hypotensive effect of 0.5% betoptic, an antiglaucoma drug manufactured by Alcon (USA), were carried out at three ophthalmologic hospitals. Similar results obtained in all the trials permit a conclusion on a high hypotensive efficacy of this drug in patients with primary open-angle glaucoma. The drug was well tolerated by the patients.
Erichev
V P
VP
Abdulkadyrova
M D
MD
Kalinina
O M
OM
Shmyreva
V F
VF
Polutornov
A L
AL
Egorov
E A
EA
Shmeleva
I A
IA
D000368:Aged; D015784:Betaxolol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004361:Drug Tolerance; D005901:Glaucoma / Q000188:drug therapy*; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008875:Middle Aged; D013997:Time Factors
D015784:Betaxolol
Klinicheskaia otsenka gipotenzivnoĭ éffektivnosti preparata "Betoptik".